ACP
LUCD icon

Arcus Capital Partners’s Lucid Diagnostics LUCD Stock Holding History

Arcus Capital Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,100
Closed -$4.22K – 241
2022
Q4 		$4.22K Buy
+3,100
New +$5.58K ﹤0.01% 305

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Arcus Capital Partners's LUCD Position: Q1 2023 in Review

Arcus Capital Partners sold out of Lucid Diagnostics (LUCD) in Q1 2023, closing a stake of 3,100 shares — an estimated $4.22K sold.

Arcus Capital Partners first reported a position in LUCD in Q4 2022 and held it in 1 quarter. The position peaked at $4.22K in Q4 2022. 19 funds tracked by Wall St. Rank hold LUCD as of Q1 2023.

  • Arcus Capital Partners reported no remaining Lucid Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Arcus Capital Partners sold 3,100 Lucid Diagnostics shares in Q1 2023, an estimated $4.22K.
  • Arcus Capital Partners first reported a position in Lucid Diagnostics in Q4 2022 and held it in 1 quarter.
  • Arcus Capital Partners's Lucid Diagnostics position peaked at $4.22K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.